Compare Lithium Americas Corp (LAC) vs Novavax Inc (NVAX) Price & Performance

Lithium Americas Corp. (LAC) trades at $3.30, up 1.54% today, with a bullish technical signal from moving averages but negative profitability metrics including an ROE of -11.35% and net loss of $122.09 million in 2025. Recent news highlights a $175 million financing to strengthen the balance sheet as Thacker Pass approaches peak construction, though earnings have been volatile with mixed quarterly beats and misses.

The outlook is balanced: analyst consensus shows 47% buy ratings with no sells, reflecting optimism on lithium demand, but high execution risk remains given negative cash flow from operations and substantial capital needs. Upside depends on successful project development, while downside risks include funding pressures and commodity price volatility.

Novavax (NVAX) trades at $7.89, down 0.75% on the day, with a bullish technical signal despite mixed indicators. The company reported a strong Q2 2026 earnings beat, raising its full-year revenue outlook, while maintaining a low valuation with a P/E of 3.14 and EV/EBITDA of 1.72. However, negative net income margin and shareholder equity highlight financial challenges.

The outlook is cautiously optimistic, driven by partnership milestones with Sanofi and cost reductions, but risks include persistent cash burn and competitive vaccine market pressures. Analyst consensus leans bullish with 74% buy ratings, suggesting potential upside if execution improves.